research use only

Pretomanid (PA-824) Bacterial inhibitor

Cat.No.S1162

Pretomanid (PA-824) is an anti-tuberculosis drug for tuberculosis with MIC less than 2.8 μM, currently in Phase 2.
Pretomanid (PA-824) Bacterial inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 359.26

Quality Control

Batch: S116201 DMSO]72 mg/mL]false]Ethanol]16 mg/mL]false]Water]Insoluble]false Purity: 99.99%
99.99

Chemical Information, Storage & Stability

Molecular Weight 359.26 Formula

C14H12F3N3O5

Storage (From the date of receipt)
CAS No. 187235-37-6 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles C1C(COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F

Solubility

In vitro
Batch:

DMSO : 72 mg/mL (200.41 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 16 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features
An experimental anti-tuberculosis drug.
Targets/IC50/Ki
tuberculosis [1]
In vitro
In vitro, PA-824 exhibits high activity against multidrug-resistant clinical isolates from Asia (India and South Korea) and from throughout the United States (MIC < 1 μg/ml) and is equally active against the drug-sensitive and multidrug-resistant isolates of M. tuberculosis (MICs range, 0.039 to 0.531 μg/ml). [1] A recent study shows that single-nucleotide polymorphisms of its resistance genes (fgd1 [Rv0407] and ddn [Rv3547]) don't significantly affect the MICs of this compound (≤ 0.25 μg/ml). [2]
In vivo
In the rapid tuberculosis mouse model, PA-824 shows significant anti-microbial activity in a dose-dependent manner: at 50 mg/kg, it in MC produces a more than 1-log reduction of the CFU in the lungs; at 100 mg/kg it produces about a 2-log reduction, and at 300 mg/kg it produces a 3-log reduction. Furthermore, long-term treatment of this compound at 100 mg/kg in cyclodextrin/lecithin also leads to the reduction of the bacterial load below 500 CFU in the lungs and spleen. [1] It exhibits time-dependent anti-microbial activity in a murine model of tuberculosis with a maximal observed bactericidal effect of 0.1 log CFU/day over 24 days. [3]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02333799 Completed
Pulmonary Tuberculosis
Global Alliance for TB Drug Development
March 2015 Phase 3
NCT01674218 Completed
Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)
September 2012 Phase 1
NCT01768273 Completed
Tuberculosis
Global Alliance for TB Drug Development
December 2009 Phase 1
NCT03202693 Completed
Tuberculosis
Global Alliance for TB Drug Development
March 2006 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.